Compare Eli Lilly And Co (LLY) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Morgan Stanley — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Morgan Stanley trades at $190.02 (market cap $294.39B). The key difference: Eli Lilly And Co is far larger — about 3.5× Morgan Stanley's market cap, and Morgan Stanley pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Morgan Stanley for 92 Days on average.
| LLY | MS | |
|---|---|---|
Market Cap | $1.04T | $294.39B |
Volume | 3,064,878 | 5,836,423 |
Sector | Health | Financials |
52-Week High | $1.28K | $228.42 |
52-Week Low | $799.57 | $151.86 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $1.09T | $660.04B |
Dividend Yield | 0.59% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Morgan Stanley (MS) trades at $187.41, down 1.21% on the day, with a bearish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing to $66.0 billion in 2025 and net income reaching $16.9 billion, alongside three consecutive quarterly EPS beats. Analysts maintain a bullish stance with a $229.25 consensus price target, citing growth in wealth management and AI financing.
The outlook is positive given earnings momentum and strategic growth areas, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to analyst targets if execution continues, though macroeconomic and capital markets volatility pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
